Capital Markets

Corporate / M&A

Financing and Investment Products

IP / IT

Vectivio

On October 13, 2022, VectivBio Holding AG (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced the release of its interim data from the first five of nine patients in its ongoing Phase 2 STARS Nutrition clinical trial, the pricing of a USD 125 m underwritten offering of ordinary shares, and an amendment to its financing agreement with Kreos Capital VI (UK) Limited, including the right to receive additional warrants under certain conditions.
The underwritten offering consists of 16,700,000 ordinary shares at an offering price of USD 7.50 per share. Investors include Cowen Healthcare Investments, Driehaus Capital Management, Eventide Asset Management, LLC, Forbion&#8217;s Growth Opportunities Fund, Frazier Life Sciences, Marshall Wace, OrbiMed, Surveyor Capital (a Citadel company), TCG X, Venrock Healthcare Capital Partners and Vivo Capital, among other specialist biotech investors.
The Homburger team includes partner Andreas Müller, associates Margrit Marti and Oliver Kneubühl, and junior associate Julien Di Sabato (all Capital Markets; Corporate / M&amp;A), partner Jürg Frick, associates Simone Gloor and Stefan Bindschedler, and junior associate Thibault Sieber (all Financing and Investment Products), partner Stefan Oesterhelt and associate Kevin Müller (both Tax), and partner Luca Dal Molin (IP / IT).

Thibault
Sieber

Homburger advises VectivBio on its USD 125 m underwritten offering and amendment to its financing agreement with Kreos Capital

Join the Team

Thibault Sieber

Career

Languages

Bar Registration

Teams

ThibaultSieber